- Record: found
- Abstract: found
- Article: not found
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux
1 ,
Ghulam J Mufti ,
Eva Hellstrom-Lindberg ,
Valeria Santini ,
Carlo Finelli ,
Aristoteles Giagounidis ,
Robert Schoch ,
Norbert Gattermann ,
Guillermo Sanz ,
Alan List ,
Steven D Gore ,
John F Seymour ,
John M Bennett ,
John Byrd ,
Jay Backstrom ,
Linda Zimmerman ,
David McKenzie ,
Cl Beach ,
Lewis R Silverman
Mar 2009
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.